Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02860286 · ClinicalTrials.gov registry record · Phase 2
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
A Phase 2 study, sponsored by Epizyme.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT02860286 is a Phase 2 study that has completed, run by Epizyme. The registered enrollment target is 74 participants.
The verdict
NCT02860286, a Phase 2 study, has completed, sponsored by Epizyme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
This is a Phase 2, multicenter, open-label, 2-part, single-arm, 2-stage study of tazemetostat 800 mg two times a day (BID) administered orally. Screening of subjects to determine eligibility for the study will be performed within 21 days of the first planned dose of tazemetostat. In Part 1: planned to enroll 12 subjects with relapsed or refractory malignant mesothelioma regardless of BAP1 status will be treated and undergo pharmacokinetics (PK) blood sample collection after a single tazemetostat 800 mg. Part 2 plans to include 55 subjects with BAP1-deficient relapsed or refractory malignant mesothelioma. Treatment with tazemetostat will continue until disease progression, unacceptable toxicity or withdrawal of consent, or termination of the study. Response assessment will be evaluated after 6 weeks of treatment and then every 12 weeks thereafter while on study.
Interventions
- DRUG Tazemetostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2016-07 |
| Est. Completion | 2019-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02860286
The ClinicalTrials.gov registry entry for NCT02860286 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Epizyme, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tazemetostat is the first listed.
NCT02860286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02860286 about?
NCT02860286 is a clinical study titled "Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma". This is a Phase 2, multicenter, open-label, 2-part, single-arm, 2-stage study of tazemetostat 800 mg two times a day (BID) administered orally. Screening of subjects to determine eligibility for the study will be performed within 21 days of the first planned dose of tazemetostat. In Part 1: planned...
What is the current status of trial NCT02860286?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2016-07. Estimated completion is 2019-05.
What interventions are being tested in trial NCT02860286?
The interventions under investigation include: Tazemetostat (DRUG).
Who is sponsoring clinical trial NCT02860286?
This trial is sponsored by Epizyme, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.